Survival rates
| Endpoint/time, mo . | Estimate for survival rate, % . | 95% CI . |
|---|---|---|
| All patients (N = 59) | ||
| OS | ||
| 12 | 92.8 | 81.9-97.2 |
| 24 | 83.3 | 70.3-91.0 |
| 36 | 66.1 | 50.1-78.0 |
| PFS | ||
| 12 | 83.5 | 70.7-91.1 |
| 24 | 65.5 | 50.8-76.7 |
| 36 | 58.4 | 43.3-70.8 |
| Time to HL-related death | ||
| 12 | 94.5 | 83.9-98.2 |
| 24 | 86.9 | 74.5-93.6 |
| 36 | 74.8 | 58.2-85.6 |
| Time to HL-related failure | ||
| 12 | 85.0 | 72.3-92.2 |
| 24 | 68.8 | 54.1-79.7 |
| 36 | 66.0 | 50.7-77.5 |
| Advanced-stage patients only (N = 55) | ||
| OS | ||
| 12 | 92.4 | 81.0-97.1 |
| 24 | 82.4 | 68.8-90.4 |
| 36 | 64.3 | 47.8-76.7 |
| PFS | ||
| 12 | 82.5 | 69.1-90.5 |
| 24 | 63.7 | 48.6-75.4 |
| 36 | 56.3 | 40.9-69.1 |
| Time to HL-related death | ||
| 12 | 94.2 | 83.0-98.1 |
| 24 | 86.2 | 73.1-93.2 |
| 36 | 73.2 | 55.8-84.7 |
| Time to HL-related failure | ||
| 12 | 84.1 | 70.7-91.7 |
| 24 | 67.2 | 52.0-78.5 |
| 36 | 64.1 | 48.4-76.2 |
| Endpoint/time, mo . | Estimate for survival rate, % . | 95% CI . |
|---|---|---|
| All patients (N = 59) | ||
| OS | ||
| 12 | 92.8 | 81.9-97.2 |
| 24 | 83.3 | 70.3-91.0 |
| 36 | 66.1 | 50.1-78.0 |
| PFS | ||
| 12 | 83.5 | 70.7-91.1 |
| 24 | 65.5 | 50.8-76.7 |
| 36 | 58.4 | 43.3-70.8 |
| Time to HL-related death | ||
| 12 | 94.5 | 83.9-98.2 |
| 24 | 86.9 | 74.5-93.6 |
| 36 | 74.8 | 58.2-85.6 |
| Time to HL-related failure | ||
| 12 | 85.0 | 72.3-92.2 |
| 24 | 68.8 | 54.1-79.7 |
| 36 | 66.0 | 50.7-77.5 |
| Advanced-stage patients only (N = 55) | ||
| OS | ||
| 12 | 92.4 | 81.0-97.1 |
| 24 | 82.4 | 68.8-90.4 |
| 36 | 64.3 | 47.8-76.7 |
| PFS | ||
| 12 | 82.5 | 69.1-90.5 |
| 24 | 63.7 | 48.6-75.4 |
| 36 | 56.3 | 40.9-69.1 |
| Time to HL-related death | ||
| 12 | 94.2 | 83.0-98.1 |
| 24 | 86.2 | 73.1-93.2 |
| 36 | 73.2 | 55.8-84.7 |
| Time to HL-related failure | ||
| 12 | 84.1 | 70.7-91.7 |
| 24 | 67.2 | 52.0-78.5 |
| 36 | 64.1 | 48.4-76.2 |